Immune checkpoint inhibitors (ICIs) are a class of drugs that block the PD1/PDL1 interaction, thereby preventing inhibitory PD1 signaling and empowering T cells to effectively eliminate cancer cells (He and Xu 2020). This evidence concerns the gene CD274 and cancer.